Liu, Chao

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

Development and external validation of a breast cancer absolute risk prediction model in Chinese population

Han, Y., Lv, J., Yu, C., Guo, Y., Bian, Z., Hu, Y., Yang, L., Chen, Y., Du, H., Zhao, F., et al. (2021) · Breast Cancer Research

Cancer Risks and FactorsGlobal Cancer Incidence and Screening

Cited by 18

Clinically Interpretable Machine Learning Models for Early Prediction of Mortality in Older Patients with Multiple Organ Dysfunction Syndrome: An International Multicenter Retrospective Study

Liu, X., DuMontier, C., Hu, P., Liu, C., Yeung, W., Mao, Z., Ho, V., Thoral, P. J., Kuo, P.-C., Hu, J., et al. (2023) · The Journals of Gerontology: Series A

Sepsis Diagnosis and TreatmentMachine Learning in Healthcare

Cited by 14